HanAll BioPharma Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1973-11-20
- Employees
- -
- Market Cap
- -
- Website
- http://www.hanall.co.kr
Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty
- Conditions
- CPP
- Interventions
- Drug: Eligard® 45 mg
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06926933
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷Jeonbuk National University Hospital, Jeonju, Korea, Republic of
🇰🇷Chosun University Hospital, Kwangju, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 750
- Registration Number
- NCT06400589
- Locations
- 🇺🇸
HanAll Site #1, Delray Beach, Florida, United States
A Study Assessing the Safety of Oral ATH-399A in Healthy Adult Participants
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 76
- Registration Number
- NCT06088784
- Locations
- 🇨🇦
Syneos Quebec Canada, Quebec, Canada
A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye
- Conditions
- Dry Eye
- Interventions
- Drug: PlaceboDrug: 0.25% Tanfanercept Ophthalmic Solution
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 260
- Registration Number
- NCT05109702
- Locations
- 🇺🇸
Cornea & Cataract Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Global Research Management, Glendale, California, United States
🇺🇸The Eye Care Institute - Butchertown Clinical Trials, Louisville, Kentucky, United States
A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes
- Conditions
- Dry Eye
- Interventions
- Biological: PlaceboBiological: HL036 Ophthalmic Solution
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 637
- Registration Number
- NCT03846453
- Locations
- 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸East West Eye Institute, Torrance, California, United States
🇺🇸Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States
A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes
- Conditions
- Dry Eye
- Interventions
- Biological: HL036 ophthalmic solutionOther: Placebo vehicle solution
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT03334539
- Locations
- 🇺🇸
Central Maine Eye Care, Lewiston, Maine, United States
🇺🇸Andover Eye Associates, Andover, Massachusetts, United States
Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)
- Conditions
- Hypertension
- Interventions
- Drug: HL068 16/10mg
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT02988362
Phase 1 Study for Safety and Tolerability of HL036
- Conditions
- Dry Eye
- Interventions
- Biological: HL036Biological: Vehicle
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2016-12-09
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02717208
- Locations
- 🇰🇷
Seoul National University Hospital,Clinical Trial Center/ Clinical Research Institute, Seoul, Korea, Republic of
Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT01806363
- Locations
- 🇰🇷
Kyungpook national university hospital Clionical center, Daegu, Gyeongsangbuk-do, Korea, Republic of
Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- HanAll BioPharma Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT01806311
- Locations
- 🇰🇷
Chungnam national university hospital,clinical trial center, Daejeon, Chungcheongbul-do, Korea, Republic of